Equities research analysts expect VIVUS, Inc. (NASDAQ:VVUS) to announce ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS posted earnings of ($0.13) per share in the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 2nd.
According to Zacks, analysts expect that VIVUS will report full-year earnings of ($0.43) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($0.57) per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow VIVUS.
VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $11.90 million for the quarter. VIVUS had a negative return on equity of 843.43% and a negative net margin of 79.80%.
Several equities research analysts have recently weighed in on VVUS shares. Zacks Investment Research upgraded shares of VIVUS from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Wednesday, May 16th. ValuEngine upgraded shares of VIVUS from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd.
Shares of VVUS remained flat at $$0.82 during mid-day trading on Thursday. 623,770 shares of the stock traded hands, compared to its average volume of 1,068,175. VIVUS has a twelve month low of $0.33 and a twelve month high of $1.32. The firm has a market capitalization of $93.33 million, a P/E ratio of -2.84 and a beta of 0.83. The company has a quick ratio of 7.94, a current ratio of 8.67 and a debt-to-equity ratio of -12.06.
In other VIVUS news, CEO John P. Amos bought 540,000 shares of the firm’s stock in a transaction dated Monday, May 14th. The stock was acquired at an average price of $0.52 per share, for a total transaction of $280,800.00. Following the completion of the purchase, the chief executive officer now owns 270,000 shares of the company’s stock, valued at $140,400. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Herm Rosenman bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 29th. The shares were acquired at an average price of $0.79 per share, with a total value of $39,500.00. Following the purchase, the director now directly owns 286,671 shares of the company’s stock, valued at approximately $226,470.09. The disclosure for this purchase can be found here. Insiders have bought 1,820,000 shares of company stock valued at $1,090,500 in the last quarter. Insiders own 4.40% of the company’s stock.
An institutional investor recently raised its position in VIVUS stock. Creative Planning boosted its position in VIVUS, Inc. (NASDAQ:VVUS) by 1,691.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 366,706 shares of the biopharmaceutical company’s stock after purchasing an additional 346,235 shares during the period. Creative Planning owned about 0.35% of VIVUS worth $184,000 as of its most recent filing with the Securities & Exchange Commission. 21.15% of the stock is currently owned by institutional investors and hedge funds.
VIVUS Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.